02 Mar. 2017
WILMINGTON, N.C., (March 2, 2017) – Pharmaceutical Product Development, LLC (PPD) today announced it has secured the fifth renewal of its long-standing contract with the Division of AIDS (DAIDS), National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH). The original NIAID/DAIDS contract was awarded in 1990, and with the latest renewal, the relationship will extend until 2024.
The renewed contract covers support for a broad scope of research related to HIV or HIV co-infections that includes monitoring therapeutic trials, prevention trials and vaccines work. As part of the relationship, PPD predicts risks to clinical trial participant safety and data integrity based on measures of site performance and other known risk factors.
“The extension of this contract will allow PPD to provide important comprehensive clinical site and study monitoring services to the NIH in some of the most pivotal and exciting directions in AIDS research,” said William Sharbaugh, chief operating officer of PPD. “We are privileged to continue our collaborative relationship with the NIH, leveraging our considerable resources as one of the world's largest CROs, while capitalizing on our in-depth knowledge of infectious diseases.”
PPD’s most recent contracts, ranging between five and seven years, have involved monitoring for an average of 150 clinical studies per contract.
PPD is a leading global contract research organization providing comprehensive, integrated drug development, laboratory and lifecycle management services. Our clients and partners include pharmaceutical, biotechnology, medical device, academic and government organizations. With offices in 47 countries and more than 18,500 professionals worldwide, PPD applies innovative technologies, therapeutic expertise and a firm commitment to quality to help clients and partners bend the cost and time curve of drug development to deliver life-changing therapies that improve health.
+1 910 558 6096
+1 910 558 6783